Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors

Eitemau Tebyg

• Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
  gan: Ogata, Ryohei, et al.
  Cyhoeddwyd: (2020)
• Cyclin‐dependent kinase (CDK) inhibitors for hormone receptor‐positive advanced breast cancer
  gan: Syn, Nicholas LX, et al.
  Cyhoeddwyd: (2018)
• Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
  gan: Thill, Marc, et al.
  Cyhoeddwyd: (2018)
• Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
  gan: Tavakolian, Shaian, et al.
  Cyhoeddwyd: (2020)
• Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
  gan: Finn, Richard S., et al.
  Cyhoeddwyd: (2016)